



Appointment of Chairman of the Board

November 3, 2021

RNS Number : 2161R

MaxCyte, Inc.

03 November 2021

MaxCyte Board Member Richard Douglas, PhD, Appointed Independent Chairman of the Board

GAITHERSBURG, MD, Nov. 3, 2021 - MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. The company today announces that its Board of Directors has appointed Richard Douglas, PhD, as Chair of the Board. Richard Douglas has been a Non-Executive Director since February 2018. He succeeds J. Stark Thompson, PhD, who previously announced his decision not to seek re-election. Dr. Thompson will remain as a consultant to MaxCyte.

"MaxCyte's EXPERT™ technology and cell engineering expertise is well-known throughout the industry and I'm extremely proud to step into the role of Board Chair on the heels of its first U.S. public offering, which marks a pivotal time in the Company's history," said Dr. Douglas.

Dr. Douglas is a veteran pharmaceutical executive who presently serves as an adviser at RedSky Partners, Chair of the Board of Aldeyra Therapeutics, a director of Novavax Inc., and Chair of the National Advisory Board of Innovation Partnerships at the University of Michigan. He formerly held the role of Senior Vice President of Corporate Development and Corporate Officer at Genzyme Corporation where he led numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. He had previously held scientific and corporate development roles at Integrated Genetics.

"Since bringing his wealth of experience to the board in 2018, Richard has been a valuable contributor as we sought to list on the Nasdaq. His new role is a natural transition for him to continue the strong, impactful leadership that MaxCyte has enjoyed under Stark's guidance of the Board since the founding of MaxCyte," commented **Doug Doerfler, Chief Executive Officer, President and Founder of MaxCyte**. "Stark helped set the foundation as we built MaxCyte to be the leading enabling platform technology in cell therapy worldwide. It has been a true honor to work with him and we thank him for his dedication and perspective."

"It has been an honor to serve on the MaxCyte board. The company is well positioned to continue providing its industry-leading technology to the rapidly expanding cell therapy development pipeline," remarked **Dr. Thompson**.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform

technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation[®] platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com

US Media Relations

Laura Morgan

+1 951-333-9110

Sam Brown Healthcare Communications

lauramorgan@sambrown.com

Nominated Adviser and Joint

Corporate Broker

+44 (0)20 7886 2500

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

UK IR Adviser

Consilium Strategic

+44 (0)203 709 5700

Communications

maxcyte@consilium-comms.com

Mary-Jane Elliott

Chris Welsh

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lse.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOABJBMTMTTMBJB